B型CpG寡聚脱氧核苷酸在细菌性疫苗中的研究进展  

Progress in research on B class CpG oligodeoxynucleotides in bacterial vaccines

作　　者：孙敏 蒋亚君(综述) 刘开云(审校) SUN Min;JIANG Yajun;LIU Kaiyun(Biopharmaceutical Research Institute of West China Hospital,Sichuan University,Chengdu 610000,Sichuan Province,China)

机构地区：[1]四川大学华西医院生物制药研究院,四川成都610000

出　　处：《中国生物制品学杂志》2024年第1期106-112,共7页Chinese Journal of Biologicals

基　　金：国家自然科学基金(32270944);四川大学华西医院学科卓越发展1·3·5工程项目(ZYXY210003)。

摘　　要：CpG寡聚脱氧核苷酸(CpG oligonucleotide,CpG ODN)是由人工合成的含有非甲基化CpG的ODN,在疾病预防及临床治疗领域具有广阔的应用前景。其中B型CpG ODN因具有强免疫刺激作用等特点被广泛用于疫苗研究中,且部分基序已进入临床试验阶段。随着临床治疗中的细菌耐药性问题日益严重,以B型CpG ODN为佐剂开展细菌性疫苗研发成为研究热点。本文对现有的B型CpG ODN 1826、2006、2007和1668等基序在细菌性疫苗中的研究现状及相关研究进展作一综述,以期为后续细菌性疫苗的开发及应用提供参考。CpG oligonucleotide(CpG ODN)is a synthetic oligodeoxynucleotide containing non-methylated CpG,which has broad application prospects in disease prevention and clinical treatment.Among them,B class CpG ODN is widely used in vaccine research because of its strong immune stimulation and some motifs have entered the clinical research stage.At the same time,the problem of bacterial resistance in clinical treatment has become increasingly serious,and the development of bacterial vaccine with B class CpG ODN as adjuvant has become a research hotspot.This paper reviewed the current research status and related progress of the existing B class CpG ODN 1826,2006,2007 and 1668 motifs in bacterial vaccines,with a view to providing a reference for the subsequent development and application of bacterial vaccines.

关 键 词：B型CpG寡聚脱氧核苷酸 佐剂 疾病防治 细菌性疫苗 

分 类 号：R979.5[医药卫生—药品]